Covid 19 Research using Clinical Trials (Home Page)
Report for D018410: Pneumonia, Bacterial NIH
(Synonyms: Pneumonia, Bacterial)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated MeSH Terms (6)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008173 | Lung Diseases, Obstructive NIH | 0.41 |
| D008171 | Lung Diseases, NIH | 0.38 |
| D011024 | Pneumonia, Viral NIH | 0.14 |
| D011014 | Pneumonia NIH | 0.07 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
| D018352 | Coronavirus Infections NIH | 0.05 |
Correlated HPO Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0006536 | Obstructive lung disease HPO | 0.45 |
| HP:0002088 | Abnormal lung morphology HPO | 0.41 |
| HP:0002090 | Pneumonia HPO | 0.07 |
There is one clinical trial.
Clinical Trials
1 Negative-PCR for Coronavirus Associated Pneumonia
Molecular testing (e.g PCR) of respiratory tract samples is the recommended method for the identification and laboratory confirmation of COVID-19 cases. Recent evidence reported that the diagnostic accuracy of many of the available RT-PCR tests for detecting SARS-CoV2 may be lower than optimal. Of course, the economical and clinical implications of diagnostic errors are of foremost significance and in case of infectious outbreaks, namely pandemics, the repercussions are amplified. False positives and false-negative results may jeopardize the health of a single patient and may affect the efficacy of containment of the outbreak and of public health policies. In particular, false-negative results contribute to the ongoing of the infection causing further spread of the virus within the community, masking also other potentially infected people.
NCT04387799 Pneumonia, Viral Pneumonia, Bacterial Coronavirus Infection Obstructive Lung Disease Diagnostic Test: Serology for Covid-19 MeSH:Pneumonia, Bacterial Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Pneumonia Lung Diseases Lung Diseases, Obstructive
HPO:Abnormal lung morphology Obstructive lung disease Pneumonia
Primary Outcomes
Description: assess if inpatients who presented with pneumonia but had a negative test for Covid-19 are positive at the serology for SARS-CoV-2.
Measure: Serology Time: 3 weeks
Secondary Outcomes
Description: to find if the combination of CT scan and serology could help us in the identification of those patients who were initially negative at laboratory testing alone.
Measure: Efficacy of CT scan and Serology Time: 3 weeks
Description: the efficacy of different pharmaceutical treatments against Covid-19
Measure: Efficacy of different pharmaceutical treatments Time: 3 weeks
HPO Nodes
Primary Outcomes
Description: assess if inpatients who presented with pneumonia but had a negative test for Covid-19 are positive at the serology for SARS-CoV-2.
Measure: Serology Time: 3 weeksSecondary Outcomes
Description: to find if the combination of CT scan and serology could help us in the identification of those patients who were initially negative at laboratory testing alone.
Measure: Efficacy of CT scan and Serology Time: 3 weeksDescription: the efficacy of different pharmaceutical treatments against Covid-19
Measure: Efficacy of different pharmaceutical treatments Time: 3 weeks